In patients aged ≥60 years with FLT3-ITD-mutated AML relapsed within 1 year of initial remission or refractory to first-line chemotherapy (cohort 1; n = 157), the CRc rate was 56% and the ORR was 77%. The gene discussed is FLT3; the disease is acute myeloid leukemia.